NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of …
Neogen Corporation, a member of Bio Nebraska, and Superior Livestock Auction have announced the launch of Igenity® Branded, a commercial beef certification program verified by a genomic test. Read more
By Macy Meyer at klkntv.com
Adjuvance is developing a component that will strengthen a vaccine and prolong its dosage.
Tucked away in one of the many labs on Nebraska’s Innovation Campus lays the company Adjuvance. At the beginning of the year they were asked by the National Institute of Health to join in on the global race to fight COVID–19. Four months later they’re making strides. Read more
The University of Nebraska–Lincoln is partnering with the Nebraska ethanol industry to produce hand sanitizer at the Food Processing Center on Innovation Campus. Read more
Submissions will be accepted April 20 – May 8 on IowaBio’s website. Read more
PhRMA – Our nation’s pharmaceutical industry, including many of Bio Nebraska’s own members, is working collectively to combat COVID-19 across the globe. Bio Nebraska member, PhRMA, highlights that work. Read more
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic. Read more
The University of Nebraska–Lincoln is partnering with the Nebraska ethanol industry to produce hand sanitizer for use by hospitals, nursing homes, doctors’ offices and other health care providers in Nebraska and nearby areas. Read more
For 2020, the BIO International Convention (June 8-12) will transition to a new, virtual event format, BIO Digital. Read more
Alex Gorsky, chairman and CEO of Johnson & Johnson, one of several companies that’s developed a potential coronavirus vaccine, tells TODAY that his company has a candidate “that has a high degree of probability of being successful.” He anticipates starting tests in humans in September …